Guardant Health, Inc. (NASDAQ:GH) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET
Company Participants
Carrie Mendivil - IR
Helmy Eltoukhy - Co-Founder, Co-CEO & Chairman
AmirAli Talasaz - Co-CEO & Director
Michael Bell - CFO
Conference Call Participants
Jack Meehan - Nephron Research
Puneet Souda - Leerink Partners
Patrick Donnelly - Citigroup
David Delahunt - Goldman Sachs Group
Daniel Leonard - Crédit Suisse
Andrew Brackmann - William Blair & Company
Sung Ji Nam - Scotiabank
Operator
Hello, everyone, and welcome to the Guardant Health Second Quarter 2023 Earnings Call. My name is Emily, and I'll be coordinating your call today. [Operator Instructions]. I'll now turn the call over to Investor Relations. Please go ahead. Thank you.
Carrie Mendivil
Earlier today, Guardant Health released financial results for the quarter ended June 30, 2023. Joining me today from Garden are Helmy Eltoukhy, Co-CEO; and AmirAli Talasaz, Co-CEO; and Mike Bell, Chief Financial Officer. Before we begin, I'd like to remind you that during this call, management will make forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. This call will also include a discussion of non-GAAP financial measures, which are adjusted to exclude certain specified items.
Additional information regarding material risks and uncertainties as well as reconciliation to most directly comparable GAAP financial measures are available in the press release Guardant issued today as well as in our Form 10-K and other filings with the SEC. Guardant disclaims any intention or obligation to update or revise financial projections and forward-looking statements, whether because of no information, future events or otherwise. The information in this conference call is accurate only as of the live broadcast. With that, I'd like to turn the call over to Helmy.
Helmy Eltoukhy
Thanks, Carrie. Good afternoon, and thank you for joining our second quarter 2023 earnings I will start off our call today with our top line results for the second quarter and go into more detail on our progress in therapy selection and MRD. I will then turn the call over to AmirAli for an update on end finally, Mike will provide a more detailed look at our financials and outlook for the remainder of 2023.
Starting on Slide 3. At Guardant, we are singularly focused on our mission to help patients across all stages of cancer live longer and healthier lives with the data provided from our powerful blood tests. In line with this priority, we will start our call up by sharing patient story. In September 2021, a 56-year-old woman had a colonoscopy that revealed colon cancer. She then had curative intent surgery, which removed 32 lymph nodes. Pathology indicated a diagnosis of stage 2 colorectal cancer with no evidence of disease in the removed lymph nodes as well as negative margins on the reception.